{"drugs":["Diatrizoate Sodium","Hypaque Sodium"],"mono":{"0":{"id":"176920-s-0","title":"Generic Names","mono":"Diatrizoate Sodium"},"1":{"id":"176920-s-1","title":"Dosing and Indications","sub":[{"id":"176920-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Aortography:<\/b> (Hypaque(TM)) 10 to 30 mL of 50% solution INTRA-ARTERIALLY by translumbar technique to visualize the aorta and its major branches OR 1 mL\/kg IV OR 0.5 to 1 mL\/kg of body weight by retrograde catheter<\/li><li><b>Arteriography, Peripheral:<\/b> (Hypaque(TM)) 25 to 35 mL of 50% solution introduced into the larger peripheral arteries by PERCUTANEOUS or operative methods<\/li><li><b>Cholangiogram, Direct:<\/b> (Hypaque(TM)) (operative) 10 to 15 mL of a 25% to 50% solution injected or instilled slowly without undue pressure into the cystic duct or common bile duct; may require a larger volume (up to 100 mL) in case of a dilated ductal tract<\/li><li><b>CT of head, Contrast enhancement:<\/b> (Hypaque(TM)) 50 to 100 mL (50% solution) bolus IV injection or up to 150 mL by infusion; rate of injection depends on the pathology<\/li><li><b>Head angiography:<\/b> (Hypaque(TM)) 8 to 10 mL of 50% solution rapidly injected at a rate not exceeding the normal flow in the carotid artery (about 5 mL per second); repeated as indicated<\/li><li><b>Head angiography:<\/b> (Hypaque(TM)) a single injection of 35 to 50 mL by retrograde brachial or catheter method (aortic arch)<\/li><li><b>Hysterosalpingography:<\/b> (Hypaque(TM)) approximately 4 mL of 50% solution to fill a normal uterine cavity, with an additional 3 mL or 4 mL for the fallopian tubes; amounts vary depending on the nature of the disease<\/li><li><b>Intraosseous venography:<\/b> (Hypaque(TM)) 10 to 20 mL of 50% solution injected directly into the bone marrow after aspirating 4 mL of marrow; to visualize the pterygoid venous plexus, inject 5 to 8 mL into the medullary cavity of the mandible<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Hypaque(TM)) 30 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated; range, 30 to 60 mL; may use 20 mL in persons of slight build<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (Hypaque(TM)) 20 to 30 mL of 50% solution IM (undiluted or diluted) injected in the gluteal muscles in 2 separate, equal doses OR SUBQ (diluted with equal quantities of sterile water for injection) injected in divided equal doses over each scapula<\/li><li><b>Percutaneous transhepatic cholangiogram:<\/b> (Hypaque(TM)) 20 to 40 mL of 50% solution (range, 10 to 60 mL), slowly injected into the biliary duct under very slight pressure; if a duct is not located by aspiration, successive small doses of 1 to 2 mL injected into the liver as the needle is gradually withdrawn, until a duct is visualized by x-ray<\/li><li><b>Radiography of gastrointestinal tract:<\/b> (Hypaque(TM) sodium oral powder) 90 to 180 mL of a 25% to 40% solution ORALLY<\/li><li><b>Radiography of gastrointestinal tract:<\/b> (Hypaque(TM) sodium oral powder) 500 to 1000 mL of a 15% to 25% solution RECTALLY<\/li><li><b>Renal arteriography, Selective:<\/b> (Hypaque(TM)) 5 to 8 mL of 50% solution with repeated injections<\/li><li><b>Splenoportogram by splenic arteriography:<\/b> (Hypaque(TM)) 20 to 25 mL of 50% solution rapidly injected; initially inject a small pilot dose to confirm splenic entry<\/li><li><b>Venography:<\/b> (Hypaque(TM)) 15 to 40 mL of 50% solution by PERCUTANEOUS or operative method to visualize veins in the extremities<\/li><\/ul>"},{"id":"176920-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Aortography:<\/b> (12 years and older) (Hypaque(TM)) 10 to 30 mL of 50% solution INTRA-ARTERIALLY by translumbar technique to visualize the aorta and its major branches OR 1 mL\/kg IV OR 0.5 to 1 mL\/kg of body weight by retrograde catheter<\/li><li><b>Aortography:<\/b> (less than 12 years of age) (Hypaque(TM)) 1 mL\/kg of 50% solution IV OR 0.5 or 1 mL\/kg of body weight INTRA-ARTERIALLY by retrograde catheter; dose of translumbar technique is proportionate to age<\/li><li><b>CT of head, Contrast enhancement:<\/b> (Hypaque(TM)) proportional to adults (50 to 100 mL (50% solution) bolus IV injection or up to 150 mL by infusion), based on weight<\/li><li><b>Head angiography:<\/b> (Hypaque(TM)) proportional to adult doses, based on weight<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (under 6 months of age) (Hypaque(TM)) 5 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (6 to 12 months of age) (Hypaque(TM)) 6 to 8 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (1 to 2 years of age) (Hypaque(TM)) 8 to 10 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (2 to 5 years of age) (Hypaque(TM)) 10 to 12 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (5 to 7 years of age) (Hypaque(TM)) 12 to 15 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (8 to 10 years of age) (Hypaque(TM)) 15 to 18 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (11 to 15 years of age) (Hypaque(TM)) 18 to 20 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (16 years or older) (Hypaque(TM)) 30 to 60 mL of 50% solution by either direct IV bolus injection or IV drip infusion; repeated in 15 to 30 minutes if indicated; range, 30 to 60 mL; may use 20 mL in persons of slight build<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (older children) (Hypaque(TM)) 20 to 30 mL of 50% solution IM (undiluted or diluted) injected in the gluteal muscles in 2 separate, equal doses OR SUBQ (diluted with equal quantities of sterile water for injection) injected in divided equal doses over each scapula<\/li><li><b>Intravenous pyelogram, Excretory urography:<\/b> (infants and young children) (Hypaque(TM)) 5 to 16 mL of 50% solution IM (undiluted or diluted) injected in the gluteal muscles in 2 separate, equal doses OR SUBQ (diluted with equal quantities of sterile water for injection) injected in divided equal doses over each scapula<\/li><li><b>Radiography of gastrointestinal tract:<\/b> (Hypaque(TM) sodium oral powder) 30 to 75 mL of a 20% to 40% solution ORALLY<\/li><li><b>Radiography of gastrointestinal tract:<\/b> (Hypaque(TM) sodium oral powder) 100 to 500 mL of a 10% to 15% solution RECTALLY, depending on patient's weight<\/li><li><b>Renal arteriography, Selective:<\/b> (older than 14 years) (Hypaque(TM)) 5 to 8 mL of 50% solution with repeated injections<\/li><li><b>Renal arteriography, Selective:<\/b> (younger than 14 years) (Hypaque(TM)) dose is proportionate to age<\/li><\/ul>"},{"id":"176920-s-1-6","title":"Dose Adjustments","mono":"(pancreatitis patients) (Hypaque(TM)) for direct cholangiography, inject no more than 5 to 10 mL without undue pressure "},{"id":"176920-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Aortography<\/li><li>Arteriography, Peripheral<\/li><li>Cholangiogram, Direct<\/li><li>CT of head, Contrast enhancement<\/li><li>Head angiography<\/li><li>Hysterosalpingography<\/li><li>Intraosseous venography<\/li><li>Intravenous pyelogram, Excretory urography<\/li><li>Percutaneous transhepatic cholangiogram<\/li><li>Radiography of gastrointestinal tract<\/li><li>Renal arteriography, Selective<\/li><li>Splenoportogram by splenic arteriography<\/li><li>Venography<\/li><\/ul>"}]},"3":{"id":"176920-s-3","title":"Contraindications\/Warnings","sub":[{"id":"176920-s-3-9","title":"Contraindications","mono":"<ul><li>when used as recommended, there are no specific contraindications for administration of oral solution and no absolute contraindication for administration of injection<\/li><li>administration into subarachnoid space; even small amounts may cause convulsions and death (injection)<\/li><li>dehydrated azotemic patients; urography and large-dose vascular procedures are contraindicated (injection)<\/li><li>epidural administration (injection)<\/li><li>intrathecal administrations; increased risk of severe adverse events (injection)<\/li><li>myelography or examination of dorsal cysts or sinuses (injection)<\/li><\/ul>"},{"id":"176920-s-3-10","title":"Precautions","mono":"<ul><li>brain metastases; increased risk of seizures when high doses of ionic contrast media are given during CT scan (injection)<\/li><li>bronchial asthma or allergy, personal or family history of; increased risk of drug hypersensitivity reaction (injection)<\/li><li>cellular injury to circulating lymphocytes; increased risk with contrast media administered for cardiac catheterization and angiocardiography (injection)<\/li><li>concomitant general anesthesia; may increase risk of adverse effects due to reduced cardiac output and increased duration of contrast agent exposure (injection)<\/li><li>congestive heart failure; risk with injection of urographic agents due to the transitory increase in the circulatory osmotic load (injection)<\/li><li>diabetes; preparatory dehydration for angiography and CT procedures may contribute to renal failure (injection)<\/li><li>diabetes with diabetic neuropathy; risk of acute renal failure following excretory urography (injection)<\/li><li>elderly patients; preparatory dehydration for angiography and CT procedures may contribute to renal failure (injection)<\/li><li>electrolyte imbalances; increased risk of shock caused by hypertonic preparations, especially in young or debilitated children and elderly cachectic patients (oral, rectal)<\/li><li>hepatic disease, severe; increased risk of adverse effects (oral, rectal, injection)<\/li><li>highly hypertonic solutions; may draw excessive amounts of contrast medium into the intestine and cause hypervolemia (oral, rectal)<\/li><li>homocystinuria, pre-existing; increased risk of inducing thrombosis and embolism with angiography (injection)<\/li><li>hypersensitivity to diatrizoic acid compounds, history of; consider benefit to risk ratio (oral or rectal)<\/li><li>hypersensitivity history or symptoms such as bronchial asthma, hay fever, and food allergies; increased risk of idiosyncratic reaction<\/li><li>hyperthyroidism or patients with an autonomously functioning thyroid nodule; risk of thyroid storm following intravascular use (injection)<\/li><li>infants and young children; preparatory dehydration for angiography and CT procedures may contribute to renal failure; increased risk of convulsions, especially with repeated injections (injection)<\/li><li>low-injection sites (L2 to L3); increased risk of neurologic complications, including paraplegia, with aortography (injection)<\/li><li>multiple myeloma; precipitation of myeloma protein in renal tubules may cause anuria, leading to progressive uremia, renal failure, and death, with excretory urography (injection)<\/li><li>pheochromocytoma, known or suspected; risk of a hypertensive crisis (injection)<\/li><li>renal disease, severe; increased risk of adverse effects (oral, rectal, or injection)<\/li><li>sensitivity to iodine or other contrast agents, history; possibility of an idiosyncratic reaction (injection)<\/li><li>sickle cell disease, homozygous; intravenous or intra-arterial administration may precipitate sickling (injection)<\/li><li>spinal anesthesia; increased risk of neurologic complications (including paraplegia) with aortography (injection)<\/li><li>subarachnoid hemorrhage; risk of clinical deterioration, including convulsions and death (injection)<\/li><li>vascular disease; increased risk for subcutaneous extravasation and sloughing of skin, especially in poorly vascularized areas (eg; dorsum of the foot or hand) (injection)<\/li><\/ul>"},{"id":"176920-s-3-11","title":"Pregnancy Category","mono":"Diatrizoate: C (FDA)<br\/>"},{"id":"176920-s-3-12","title":"Breast Feeding","mono":"<ul><li>Diatrizoate: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Diatrizoate: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"176920-s-4","title":"Drug Interactions","sub":[{"id":"176920-s-4-13","title":"Contraindicated","mono":"<ul>Metformin (theoretical)<\/ul>"},{"id":"176920-s-4-14","title":"Major","mono":"<ul>Propranolol (theoretical)<\/ul>"}]},"5":{"id":"176920-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Vasodilatation (49%)<\/li><li><b>Dermatologic:<\/b>Injection site pain (about 12%), Urticaria (1%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (6%), Taste sense altered (11%), Vomiting (3%)<\/li><li><b>Neurologic:<\/b>Dizziness (5%), Paresthesia (6%)<\/li><li><b>Renal:<\/b>Hypokalemic nephropathy (23% (after excretory urography))<\/li><li><b>Respiratory:<\/b>Cough (2%), Rhinitis (1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest (less than 1%), Shock (0.005%), Ventricular fibrillation (less than 1%)<\/li><li><b>Dermatologic:<\/b>Necrosis \/ ulceration of skin due to extravasation of drug (less than 1%)<\/li><li><b>Hematologic:<\/b>Thrombocytopenia (less than 1%)<\/li><li><b>Neurologic:<\/b>Coma (less than 1%), Paralysis (less than 1%), Seizure (less than 1%)<\/li><li><b>Renal:<\/b>Renal failure (less than 1%)<\/li><li><b>Respiratory:<\/b>Bronchospasm (less than 1%), Pulmonary edema (less than 1%)<\/li><\/ul>"},"6":{"id":"176920-s-6","title":"Drug Name Info","sub":{"0":{"id":"176920-s-6-17","title":"US Trade Names","mono":"Hypaque Sodium<br\/>"},"2":{"id":"176920-s-6-19","title":"Class","mono":"Radiological Ionic Contrast Media<br\/>"},"3":{"id":"176920-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"176920-s-7","title":"Mechanism Of Action","mono":"The use of diatrizoate is not based on its pharmacologic properties, but on its distribution and elimination from the body. The iodine content of a contrast media is the most important factor, since this component is responsible for the absorption of radiation and the degree of opacification.  The high atomic weight of iodine contributes sufficient x-radiation attenuation to impart radiographic contrast with surrounding tissue.  Diagnostic radiopaque agents have few known pharmacological effects.<br\/>"},"8":{"id":"176920-s-8","title":"Pharmacokinetics","sub":[{"id":"176920-s-8-23","title":"Absorption","mono":"Oral: 0.04% to 1.2% <br\/>"},{"id":"176920-s-8-24","title":"Distribution","mono":"Protein binding: 0% to 10% bound to serum albumin <br\/>"},{"id":"176920-s-8-25","title":"Metabolism","mono":"not metabolized <br\/>"},{"id":"176920-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: (intravenous), less than 2%<\/li><li>Renal: (intravenous), 12% within 10 minutes, 38% at 60 minutes, 45% at 3 hours, and 94% to 100% at 24 hours excreted unchanged<\/li><\/ul>"},{"id":"176920-s-8-27","title":"Elimination Half Life","mono":"Adults: (intravenous), 120 min <br\/>"}]},"9":{"id":"176920-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>do NOT administer by intrathecal route<\/li><li>solution should be at body temperature when injected; may need to be warmed<\/li><li>if crystallization occurs, place the vial in a water bath at 40 to 50 degrees C and shake it gently for 2 to 3 minutes or until solids redissolve; discard the vial if particles still persist<\/li><li>solution may be autoclaved once<\/li><li>do not contaminate catheters, syringes, needles, and contrast media with glove powder or cotton fibers<\/li><li>discard any unused portion<\/li><li>(angiography), flush the catheter frequently with heparinized saline solutions; use plastic syringes in place of glass to decrease the likelihood of in vitro clotting<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>(Hypaque(TM) sodium oral powder) use 1, 1.5, 2, 2.5, or 4 measuring spoons of powder (approximately 10 g of powder per measuring spoon level) per 100 mL of diluent (eg; water, milk, or a carbonated drink) to make 10%, 15%, 20%, 25%, or 40% solutions, respectively<\/li><li>use solution immediately after preparation and discard after use<\/li><\/ul><\/li><li><b>Rectal<\/b><br\/><ul><li>(Hypaque(TM) sodium oral powder) use 1, 1.5, 2, 2.5, or 4 measuring spoons of powder (approximately 10 g of powder per measuring spoon level) per 100 mL of diluent (eg; water, milk, or a carbonated drink) to make 10%, 15%, 20%, 25%, or 40% solutions, respectively<\/li><li>use solution immediately after preparation and discard after use<\/li><\/ul><\/li><\/ul>"},"10":{"id":"176920-s-10","title":"Monitoring","mono":"<ul><li>image quality and diagnostic usefulness<\/li><li>vital signs; baseline and then periodically<\/li><li>ECG; baseline and then periodically as clinically indicated<\/li><li>injection site reactions; frequently for any signs of extravasation<\/li><li>renal and hepatic function; baseline and then periodically as clinically indicated<\/li><li>signs and symptoms of iodine or other contrast agents sensitivity; during procedure and then for 30 to 60 minutes after the procedure<\/li><li>thyroid function tests (T3 resin uptake and total or free thyroxine (T4) assays); at baseline and after procedure as clinically indicated<\/li><\/ul>"},"13":{"id":"176920-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as the injection drug may cause dizziness.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position, as the injection drug may cause hypotension.<\/li><li>The oral form of this drug may cause nausea, vomiting, diarrhea, and urticaria.<\/li><li>The injection form of this drug may cause vasodilation, paresthesia, nausea, vomiting, cough, and perversion of taste.<\/li><li>Advise patient to report signs\/symptoms of thyroid storm (chest pain, tachycardia, dyspnea, fever, anxiety).<\/li><li>Instruct patients to be fully hydrated before procedures (with the possible exception of urography).<\/li><\/ul>"}}}